EGFR inhibitors show higher response rates but no survival advantage over bevacizumab in CRLM
Comparing two types of drugs for colorectal cancer liver metastases
This meta-analysis of 795 patients with RAS wild-type colorectal liver metastases found that EGFR inhibitor regimens yielded statistically s…
New data compares two different drug combinations for colorectal cancer that has spread to the liver to see which helps patients live longer…
BRAF-directed regimens linked to 22.3-month median OS in BRAF-mutant mCRC
Comparing Different Targeted Treatments for Patients with BRAF Mutant Colorectal Cancer
This reconstructed individual patient data meta-analysis pooled 18 randomized trials (11,931 patients) to compare targeted therapy classes i…
New data shows that treatments targeting the BRAF mutation offer a longer life expectancy than other targeted therapies.
First-line EGFR inhibitor options for advanced NSCLC require balancing efficacy with patient-centered tolerability trade-offs
New Treatment Options for Lung Cancer Patients with EGFR Mutations
This narrative review examines first-line therapy options for patients with advanced EGFR-mutated non-small cell lung cancer. The authors co…
Newer first-line therapies for lung cancer offer more options, but doctors must balance the strength of the drug against how well a patient …
PIK3CA and BRAF mutations are associated with worse progression-free and overall survival in mCRC
Specific genetic mutations may impact colorectal cancer treatment success
This meta-analysis of 1478 patients with RAS wild-type metastatic colorectal cancer evaluates the impact of PIK3CA and BRAF mutations on out…
Two specific genetic mutations, PIK3CA and BRAF, are linked to worse survival outcomes for patients with certain types of colorectal cancer.
Honeysuckle therapy improves clinical management of EGFR inhibitor-related skin rash in patients
Honeysuckle Therapy May Help Manage Skin Rashes from EGFR Inhibitors
This meta-analysis of 534 patients evaluated honeysuckle therapy for managing EGFR inhibitor-related skin rash. The analysis found that hone…
Honeysuckle therapy may delay the onset and reduce the severity of skin rashes caused by certain cancer treatments like EGFR inhibitors.
EGFR inhibitors show reproducible activity and manageable toxicity in locally advanced or metastatic anal squamous cell carcinoma
EGFR Inhibitors Show Activity in Advanced Anal Squamous Cell Carcinoma
This meta-analysis of 404 patients evaluated EGFR inhibitors (cetuximab and panitumumab) for anal squamous cell carcinoma. The analysis foun…
New analysis shows that EGFR inhibitors like cetuximab and panitumumab may improve response rates for patients with advanced anal squamous c…
Narrative review examines driver mutations and immunotherapy response in non-small cell lung cancer
Does your lung cancer's genetic makeup change how well immune therapy works?
This narrative review explores how targetable driver gene alterations in non-small cell lung cancer (NSCLC) influence the tumor immune micro…
Lung cancer's genetic drivers actively reshape the tumor's immune environment, causing immunotherapy to work differently depending on a pati…